BCAL Diagnostics (ASX:BDX) Shares Outstanding (Basic Average): 366.11 Mil (As of Dec. 2025)


What is BCAL Diagnostics Shares Outstanding (Basic Average)?

BCAL Diagnostics ASX:BDX +10.96% Shares Outstanding (Basic Average) is 366.11 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. BCAL Diagnostics's average basic shares outstanding for the quarter that ended in Dec. 2025 was 366.11 Mil.

BCAL Diagnostics  (ASX:BDX) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

BCAL Diagnostics Shares Outstanding (Basic Average) Related Terms

BCAL Diagnostics Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics Shares Outstanding (Basic Average) Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Shares Outstanding (Basic Average)
204.29 210.90 246.23 359.60

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only 231.40 261.05 365.97 353.22 366.11

BCAL Diagnostics Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 366.11 Mil mean?
BCAL Diagnostics (ASX:BDX) has a Shares Outstanding (Basic Average) of 366.11 Mil as of Dec. 2025. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on BCAL Diagnostics and its competitors.
Is BCAL Diagnostics' Shares Outstanding (Basic Average) too high?
BCAL Diagnostics' current Shares Outstanding (Basic Average) is 366.11 Mil.
How does BCAL Diagnostics' Shares Outstanding (Basic Average) compare to TMO and DHR?
BCAL Diagnostics' Shares Outstanding (Basic Average) of 366.11 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Medical Diagnostics & Research company?
A good Shares Outstanding (Basic Average) depends on the Medical Diagnostics & Research industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on BCAL Diagnostics and its competitors. BCAL Diagnostics's current Shares Outstanding (Basic Average) is 366.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Shares Outstanding (Basic Average) of 366.11 Mil. The current Shares Outstanding (Basic Average) is 366.11 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Shares Outstanding (Basic Average) is 366.11 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.